Biological evaluation and interconversion studies of rotamers of SCH 351125, an orally bioavailable CCR5 antagonist

Anandan Palani; Sherry Shapiro; John W Clader; William J Greenlee; David Blythin; Kathleen Cox; Nicole E Wagner; Julie Strizki; Bahige M Baroudy; Niya Dan

doi:10.1016/s0960-894x(02)01062-4

Biological evaluation and interconversion studies of rotamers of SCH 351125, an orally bioavailable CCR5 antagonist

Bioorg Med Chem Lett. 2003 Feb 24;13(4):705-8. doi: 10.1016/s0960-894x(02)01062-4.

Authors

Anandan Palani¹, Sherry Shapiro, John W Clader, William J Greenlee, David Blythin, Kathleen Cox, Nicole E Wagner, Julie Strizki, Bahige M Baroudy, Niya Dan

Affiliation

¹ Chemical Research, Schering-Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, NJ 07033, USA. anandan.palani@spcorp.com

PMID: 12639563
DOI: 10.1016/s0960-894x(02)01062-4

Abstract

The separation and biological evaluation of rotamers as well as interconversion studies on rotamers of our clinical candidate SCH 351125 are described.

MeSH terms

Anti-HIV Agents / chemistry*
Anti-HIV Agents / pharmacology
Biological Availability
CCR5 Receptor Antagonists*
Chemokine CCL5 / antagonists & inhibitors
Chromatography, High Pressure Liquid
Cyclic N-Oxides / chemistry*
Cyclic N-Oxides / pharmacology*
HIV / drug effects
Humans
Inhibitory Concentration 50
Isomerism
Oximes
Piperidines*
Pyridines / chemistry*
Pyridines / pharmacology*
Stereoisomerism

Substances

Anti-HIV Agents
CCR5 Receptor Antagonists
Chemokine CCL5
Cyclic N-Oxides
Oximes
Piperidines
Pyridines
Ancriviroc